

Prashant Kapoor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4474873/publications.pdf>

Version: 2024-02-01

456
papers

9,838
citations

43973

48
h-index

58464

82
g-index

461
all docs

461
docs citations

461
times ranked

7561
citing authors

#	ARTICLE	IF	CITATIONS
1	Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. <i>Leukemia</i> , 2014, 28, 1122-1128.	3.3	1,128
2	Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. <i>Mayo Clinic Proceedings</i> , 2013, 88, 360-376.	1.4	440
3	Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. <i>Blood</i> , 2017, 129, 2111-2119.	0.6	249
4	Prognostic Factors and Outcomes of Adults With Hemophagocytic Lymphohistiocytosis. <i>Mayo Clinic Proceedings</i> , 2014, 89, 484-492.	1.4	244
5	Coexistent Multiple Myeloma or Increased Bone Marrow Plasma Cells Define Equally High-Risk Populations in Patients With Immunoglobulin Light Chain Amyloidosis. <i>Journal of Clinical Oncology</i> , 2013, 31, 4319-4324.	0.8	193
6	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. <i>Blood Cancer Journal</i> , 2018, 8, 59.	2.8	171
7	Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2013, 31, 4529-4535.	0.8	147
8	Idiopathic Systemic Capillary Leak Syndrome (Clarkson's Disease): The Mayo Clinic Experience. <i>Mayo Clinic Proceedings</i> , 2010, 85, 905-912.	1.4	137
9	Therapy for Relapsed Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2017, 92, 578-598.	1.4	115
10	Diagnosis and Management of Waldenström Macroglobulinemia. <i>JAMA Oncology</i> , 2017, 3, 1257.	3.4	110
11	Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. <i>Leukemia</i> , 2014, 28, 2060-2065.	3.3	109
12	Treatment of Immunoglobulin Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1054-1081.	1.4	106
13	Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. <i>Leukemia</i> , 2011, 25, 689-696.	3.3	104
14	Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. <i>Journal of Clinical Oncology</i> , 2018, 36, 1323-1329.	0.8	100
15	Anti-CD20 monoclonal antibody therapy in multiple myeloma. <i>British Journal of Haematology</i> , 2008, 141, 135-148.	1.2	98
16	Cardiac Amyloidosis: A Practical Approach to Diagnosis and Management. <i>American Journal of Medicine</i> , 2011, 124, 1006-1015.	0.6	97
17	Hematologic Characteristics of Proliferative Glomerulonephritides With Nonorganized Monoclonal Immunoglobulin Deposits. <i>Mayo Clinic Proceedings</i> , 2015, 90, 587-596.	1.4	92
18	Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. <i>Leukemia</i> , 2017, 31, 1562-1569.	3.3	92

#	ARTICLE	IF	CITATIONS
19	Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2015, 5, e296-e296.	2.8	90
20	Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents. <i>Leukemia</i> , 2016, 30, 2208-2213.	3.3	87
21	A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE [®] (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM). <i>Blood</i> , 2020, 136, 28-29.	0.6	83
22	Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy. <i>Blood Cancer Journal</i> , 2015, 5, e364-e364.	2.8	81
23	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. <i>Bone Marrow Transplantation</i> , 2019, 54, 353-367.	1.3	81
24	Outcomes of patients with renal monoclonal immunoglobulin deposition disease. <i>American Journal of Hematology</i> , 2016, 91, 1123-1128.	2.0	76
25	Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. <i>American Journal of Hematology</i> , 2017, 92, 668-673.	2.0	75
26	Outcomes of patients with POEMS syndrome treated initially with radiation. <i>Blood</i> , 2013, 122, 68-73.	0.6	74
27	Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2017, 92, 908-917.	1.4	72
28	Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. <i>Leukemia</i> , 2019, 33, 531-536.	3.3	72
29	N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2016, 91, 1129-1134.	2.0	71
30	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. <i>Annals of Hematology</i> , 2018, 97, 1417-1425.	0.8	71
31	Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. <i>Blood Cancer Journal</i> , 2015, 5, e338-e338.	2.8	68
32	Natural history of t(11;14) multiple myeloma. <i>Leukemia</i> , 2018, 32, 131-138.	3.3	67
33	Bortezomib Combination Therapy in Multiple Myeloma. <i>Seminars in Hematology</i> , 2012, 49, 228-242.	1.8	66
34	Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2019, 37, 1403-1411.	0.8	65
35	Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. <i>Leukemia</i> , 2018, 32, 2240-2249.	3.3	64
36	Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 116.	2.8	64

#	ARTICLE	IF	CITATIONS
37	Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression. <i>Leukemia</i> , 2017, 31, 130-135.	3.3	63
38	Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death. <i>Blood Cancer Journal</i> , 2015, 5, e310-e310.	2.8	62
39	A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing. <i>Mayo Clinic Proceedings</i> , 2019, 94, 472-483.	1.4	59
40	Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. <i>Blood Cancer Journal</i> , 2020, 10, 82.	2.8	59
41	Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. <i>Blood Advances</i> , 2020, 4, 3509-3519.	2.5	58
42	Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. <i>American Journal of Hematology</i> , 2016, 91, 585-589.	2.0	57
43	Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma. <i>Leukemia</i> , 2016, 30, 633-639.	3.3	57
44	Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2017, 7, e600-e600.	2.8	57
45	Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 86-92.	1.4	57
46	MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018, 93, 187-194.	2.0	57
47	Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. <i>Blood Cancer Journal</i> , 2016, 6, e454-e454.	2.8	56
48	Evidence for Cytogenetic and Fluorescence In Situ Hybridization Risk Stratification of Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies. <i>Mayo Clinic Proceedings</i> , 2010, 85, 532-537.	1.4	55
49	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. <i>Blood</i> , 2017, 130, 1198-1204.	0.6	54
50	Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. <i>Blood Cancer Journal</i> , 2021, 11, 10.	2.8	53
51	Autologous stem cell transplant for multiple myeloma patients 70 years or older. <i>Bone Marrow Transplantation</i> , 2016, 51, 1449-1455.	1.3	51
52	Prevalence, incidence and survival of smoldering multiple myeloma in the United States. <i>Blood Cancer Journal</i> , 2016, 6, e486-e486.	2.8	49
53	Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 179-186.	2.0	49
54	Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 598-605.	2.0	47

#	ARTICLE	IF	CITATIONS
55	Induction therapy preautologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. <i>American Journal of Hematology</i> , 2016, 91, 984-988.	2.0	45
56	Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains. <i>Leukemia</i> , 2018, 32, 729-735.	3.3	44
57	Systemic Immunoglobulin Light Chain Amyloidosis Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1354-1361.	1.4	43
58	Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88L265P Mutations. <i>American Journal of Clinical Pathology</i> , 2016, 145, 843-851.	0.4	43
59	Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. <i>Leukemia</i> , 2022, 36, 801-808.	3.3	43
60	Results from Lummicar-2: A Phase 1b/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Patients with Relapsed and/or Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 28-29.	0.6	42
61	Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation. <i>American Journal of Hematology</i> , 2017, 92, 50-55.	2.0	41
62	Impact of acquired del(17p) in multiple myeloma. <i>Blood Advances</i> , 2019, 3, 1930-1938.	2.5	41
63	Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. <i>British Journal of Haematology</i> , 2020, 188, 394-403.	1.2	41
64	Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. <i>British Journal of Haematology</i> , 2019, 187, 588-594.	1.2	40
65	IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. <i>Leukemia</i> , 2020, 34, 1373-1382.	3.3	40
66	Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma. <i>Blood Cancer Journal</i> , 2017, 7, e528-e528.	2.8	39
67	Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. <i>Leukemia</i> , 2018, 32, 1567-1574.	3.3	39
68	Outcomes of primary refractory multiple myeloma and the impact of novel therapies. <i>American Journal of Hematology</i> , 2015, 90, 981-985.	2.0	38
69	Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. <i>Blood Cancer Journal</i> , 2016, 6, e512-e512.	2.8	38
70	Myelomatous Involvement of the Central Nervous System. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 644-654.	0.2	38
71	Natural history of multiple myeloma with de novo del(17p). <i>Blood Cancer Journal</i> , 2019, 9, 32.	2.8	38
72	Waldenström macroglobulinemia: What a hematologist needs to know. <i>Blood Reviews</i> , 2015, 29, 301-319.	2.8	37

#	ARTICLE	IF	CITATIONS
73	Enhancing the Râ€SS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. American Journal of Hematology, 2020, 95, 310-315.	2.0	37
74	Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both. Leukemia and Lymphoma, 2015, 56, 3357-3364.	0.6	36
75	Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. American Journal of Hematology, 2019, 94, 1020-1026.	2.0	36
76	Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. Leukemia, 2019, 33, 527-531.	3.3	36
77	Venetoclax for the treatment of translocation (11;14) AL amyloidosis. Blood Cancer Journal, 2020, 10, 55.	2.8	36
78	Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. American Journal of Hematology, 2020, 95, 497-502.	2.0	35
79	Update on risk stratification and treatment of newly diagnosed multiple myeloma. International Journal of Hematology, 2011, 94, 310-320.	0.7	33
80	Impact of MYD88^{L265P} mutation status on histological transformation of WaldenstrÃ¶m Macroglobulinemia. American Journal of Hematology, 2020, 95, 274-281.	2.0	33
81	Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatment. Leukemia, 2016, 30, 1079-1085.	3.3	32
82	Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. Clinical Cancer Research, 2020, 26, 6581-6588.	3.2	32
83	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. Mayo Clinic Proceedings, 2021, 96, 1546-1577.	1.4	32
84	Soluble suppression of tumorigenicity 2 (s<scp>ST</scp>2), but not galactinâ€³, adds to prognostication in patients with systemic <scp>AL</scp> amyloidosis independent of <scp>NT</scp>â€pro<scp>BNP</scp> and troponin <scp>T</scp>. American Journal of Hematology, 2015, 90, 524-528.	2.0	31
85	Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma. Leukemia, 2013, 27, 2062-2066.	3.3	30
86	Clinical characteristics and outcomes in biclonal gammopathies. American Journal of Hematology, 2016, 91, 473-475.	2.0	30
87	Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma. Blood Cancer Journal, 2016, 6, e401-e401.	2.8	30
88	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. Leukemia, 2017, 31, 92-99.	3.3	30
89	Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival. Bone Marrow Transplantation, 2017, 52, 1126-1132.	1.3	30
90	The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents. Bone Marrow Transplantation, 2017, 52, 34-40.	1.3	30

#	ARTICLE	IF	CITATIONS
91	A simple additive staging system for newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, 21.	2.8	30
92	Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation. <i>Haematologica</i> , 2017, 102, 1439-1445.	1.7	29
93	Fifty-Year Incidence of Waldenström Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review. <i>Mayo Clinic Proceedings</i> , 2018, 93, 739-746.	1.4	29
94	Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. <i>Blood Cancer Journal</i> , 2018, 8, 125.	2.8	29
95	Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. <i>Leukemia</i> , 2020, 34, 1135-1143.	3.3	29
96	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. <i>Leukemia</i> , 2018, 32, 1811-1815.	3.3	28
97	Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. <i>Leukemia</i> , 2019, 33, 790-794.	3.3	28
98	Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Waldenström Macroglobulinemia (WM). <i>Blood</i> , 2014, 124, 1715-1715.	0.6	28
99	“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience. <i>Blood Cancer Journal</i> , 2021, 11, 196.	2.8	28
100	Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation. <i>Leukemia</i> , 2018, 32, 712-718.	3.3	27
101	Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis. <i>Blood Cancer Journal</i> , 2020, 10, 20.	2.8	26
102	Doxycycline Used As Post Transplant Antibacterial Prophylaxis Improves Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Stem Cell Transplantation.. <i>Blood</i> , 2012, 120, 3138-3138.	0.6	26
103	Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy. <i>Leukemia</i> , 2015, 29, 2033-2038.	3.3	25
104	The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1284-1289.	0.4	25
105	Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenström macroglobulinemia. <i>British Journal of Haematology</i> , 2017, 179, 98-105.	1.2	25
106	Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. <i>American Journal of Hematology</i> , 2017, 92, 1146-1155.	2.0	25
107	Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 13-16.	1.4	25
108	MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. <i>Blood Cancer Journal</i> , 2021, 11, 50.	2.8	25

#	ARTICLE	IF	CITATIONS
109	Clinical Features and Treatment Outcomes of Patients With Necrobiotic Xanthogranuloma Associated With Monoclonal Gammopathies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 447-452.	0.2	24
110	Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis. <i>American Journal of Hematology</i> , 2017, 92, 549-554.	2.0	24
111	Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018, 93, 1384-1393.	2.0	24
112	A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis. <i>Blood Cancer Journal</i> , 2020, 10, 41.	2.8	24
113	Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant. <i>European Journal of Haematology</i> , 2014, 92, 485-490.	1.1	23
114	Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. <i>Blood Advances</i> , 2018, 2, 769-776.	2.5	23
115	The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. <i>Leukemia Research</i> , 2016, 44, 32-39.	0.4	22
116	Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 114-124.	1.2	22
117	Comparative analysis of staging systems in AL amyloidosis. <i>Leukemia</i> , 2019, 33, 811-814.	3.3	22
118	POEMS Syndrome: an Enigma. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 85-95.	1.2	21
119	Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2127-2132.	2.0	21
120	Implications of detecting serum monoclonal protein by MASSAfix following stem cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2021, 193, 380-385.	1.2	21
121	Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. <i>American Journal of Hematology</i> , 2021, 96, 1131-1136.	2.0	21
122	Clinical Profile of Single-Agent Oprozomib in Patients (Pts) with Multiple Myeloma (MM): Updated Results from a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study. <i>Blood</i> , 2014, 124, 34-34.	0.6	21
123	Consolidation and Maintenance Therapies for Newly Diagnosed Multiple Myeloma in the Era of Novel Agents. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 127-136.	1.2	20
124	Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset. <i>Leukemia</i> , 2018, 32, 1414-1420.	3.3	20
125	Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e108-e111.	2.0	20
126	Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. <i>Leukemia</i> , 2019, 33, 730-738.	3.3	20

#	ARTICLE	IF	CITATIONS
127	Prevalence and survival of smouldering Waldenström macroglobulinaemia in the United States. <i>British Journal of Haematology</i> , 2019, 184, 1014-1017.	1.2	20
128	“Direct to Drug” screening as a precision medicine tool in multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 54.	2.8	20
129	Utility and prognostic value of ¹⁸ F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 1518-1523.	2.0	19
130	Ixazomib: a novel drug for multiple myeloma. <i>Expert Review of Hematology</i> , 2018, 11, 761-771.	1.0	19
131	Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. <i>American Journal of Hematology</i> , 2015, 90, 888-891.	2.0	18
132	Sex-based disparities in venous thromboembolism outcomes: A National Inpatient Sample (NIS)-based analysis. <i>Vascular Medicine</i> , 2017, 22, 121-127.	0.8	18
133	Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, 306-311.	2.0	18
134	Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 70.	2.8	18
135	Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. <i>Blood Cancer Journal</i> , 2020, 10, 4.	2.8	18
136	Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy. <i>Bone Marrow Transplantation</i> , 2016, 51, 1156-1158.	1.3	17
137	First report of MYD88L265P somatic mutation in IgM-associated light-chain amyloidosis. <i>Blood</i> , 2016, 127, 2936-2938.	0.6	17
138	Smoldering Multiple Myeloma. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 65-71.	1.0	17
139	Clinical features, laboratory characteristics and outcomes of patients with renal <i>versus</i> cardiac light chain amyloidosis. <i>British Journal of Haematology</i> , 2019, 185, 701-707.	1.2	17
140	Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis. <i>American Journal of Hematology</i> , 2019, 94, E141-E143.	2.0	17
141	Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio. <i>American Journal of Hematology</i> , 2020, 95, 1280-1287.	2.0	17
142	Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2017, 58, 308-315.	0.6	16
143	Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. <i>American Journal of Hematology</i> , 2017, 92, 435-440.	2.0	16
144	Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2018, 93, 56-58.	1.4	16

#	ARTICLE	IF	CITATIONS
145	Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 106.	2.8	16
146	Challenges and Strategies in the Management of Multiple Myeloma in the Elderly Population. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 70-82.	1.2	16
147	Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. <i>Mayo Clinic Proceedings</i> , 2021, 96, 677-687.	1.4	16
148	A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808). <i>Blood</i> , 2020, 136, 20-21.	0.6	16
149	Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2019, 94, 455-464.	1.4	16
150	Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosis. <i>Journal of Internal Medicine</i> , 2017, 281, 611-619.	2.7	15
151	Elevation of serum lactate dehydrogenase in <scp>AL</scp> amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. <i>British Journal of Haematology</i> , 2017, 178, 888-895.	1.2	15
152	Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation. <i>British Journal of Haematology</i> , 2018, 182, 71-77.	1.2	15
153	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. <i>American Journal of Hematology</i> , 2019, 94, 751-756.	2.0	15
154	Revisiting complete response in light chain amyloidosis. <i>Leukemia</i> , 2020, 34, 1472-1475.	3.3	15
155	Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 596-601.	0.2	15
156	Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents. <i>Bone Marrow Transplantation</i> , 2021, 56, 1144-1150.	1.3	15
157	Clinical Presentation and Outcome of Patients with Myeloid Differentiation Factor 88 Gene (MYD88) Wild-Type Waldenström Macroglobulinemia. <i>Blood</i> , 2016, 128, 2960-2960.	0.6	15
158	Time to plateau as a predictor of survival in newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 889-894.	2.0	14
159	Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2360-2364.	2.0	14
160	Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. <i>American Journal of Hematology</i> , 2019, 94, 1066-1071.	2.0	14
161	Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. <i>American Journal of Hematology</i> , 2020, 95, 4-9.	2.0	14
162	New developments in the management of Waldenström macroglobulinemia. <i>Cancer Management and Research</i> , 2017, Volume 9, 73-83.	0.9	13

#	ARTICLE	IF	CITATIONS
163	Pomalidomide+dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial. <i>Leukemia</i> , 2018, 32, 719-728.	3.3	13
164	A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis. <i>Kidney International</i> , 2021, 99, 707-715.	2.6	13
165	Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (<scp>VRd</scp>) as first-line therapy in multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, 330-337.	2.0	13
166	Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019, 134, 864-864.	0.6	13
167	Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma. <i>Blood Advances</i> , 2022, 6, 2763-2772.	2.5	13
168	Prognostic factors and indications for treatment of Waldenström's Macroglobulinemia. <i>Best Practice and Research in Clinical Haematology</i> , 2016, 29, 179-186.	0.7	12
169	Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection. <i>Current Treatment Options in Oncology</i> , 2016, 17, 16.	1.3	12
170	Substratification of patients with newly diagnosed standard-risk multiple myeloma. <i>British Journal of Haematology</i> , 2019, 185, 254-260.	1.2	12
171	Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. <i>Leukemia</i> , 2019, 33, 1273-1277.	3.3	12
172	Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. <i>Blood Cancer Journal</i> , 2020, 10, 124.	2.8	12
173	Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. <i>American Journal of Hematology</i> , 2020, 95, 637-642.	2.0	12
174	Coagulation Abnormalities in Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2021, 96, 377-387.	1.4	12
175	Assessment of fixed-duration therapies for treatment-naïve <scp>Waldenström</scp> macroglobulinemia. <i>American Journal of Hematology</i> , 2021, 96, 945-953.	2.0	12
176	Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2021, 195, 210-216.	1.2	12
177	Lenalidomide Maintenance Therapy In Multiple Myeloma: A Meta-Analysis Of Randomized Trials. <i>Blood</i> , 2013, 122, 407-407.	0.6	12
178	Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. <i>Leukemia</i> , 2022, 36, 873-876.	3.3	12
179	Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL). <i>American Journal of Hematology</i> , 2018, 93, 17-22.	2.0	11
180	Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multiparametric flow cytometry method. <i>American Journal of Hematology</i> , 2019, 94, 424-430.	2.0	11

#	ARTICLE	IF	CITATIONS
181	A prognostic index predicting survival in transformed Waldenström macroglobulinemia. <i>Haematologica</i> , 2021, 106, 2940-2946.	1.7	11
182	Trends and Outcomes in Allogeneic Hematopoietic Stem Cell Transplant for Multiple Myeloma at Mayo Clinic. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 349-357.e2.	0.2	10
183	First report of <i>MYD88</i> ^{L265P} somatic mutation in IgM-associated light chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 42-43.	1.4	10
184	Natural history of amyloidosis isolated to fat and bone marrow aspirate. <i>British Journal of Haematology</i> , 2017, 179, 170-172.	1.2	10
185	Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. <i>Haematologica</i> , 2018, 103, 1229-1234.	1.7	10
186	MAIA under the microscope – bringing trial design into focus. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 339-340.	12.5	10
187	Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma. <i>American Journal of Hematology</i> , 2020, 95, E8-E10.	2.0	10
188	Monoclonal Gammopathy of Undetermined Significance: Current Concepts and Future Prospects. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 45-55.	1.2	10
189	Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS). <i>Blood Cancer Journal</i> , 2021, 11, 26.	2.8	10
190	Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018, 132, 304-304.	0.6	10
191	Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. <i>Haematologica</i> , 2016, 101, 1102-1109.	1.7	9
192	Fresh perspectives on treatment and moments of clarity. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 73-74.	12.5	9
193	Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 587-594.	1.3	9
194	Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 101-102.	1.4	9
195	The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 2039-2050.	1.3	9
196	Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1520-1525.	2.0	9
197	Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function. <i>Bone Marrow Transplantation</i> , 2019, 54, 1775-1779.	1.3	9
198	Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 31-43.	1.2	9

#	ARTICLE	IF	CITATIONS
199	Kidney Transplantation in Patients With Monoclonal Gammopathy of Renal Significance (MGRS)â€™Associated Lesions: A Case Series. American Journal of Kidney Diseases, 2022, 79, 202-216.	2.1	9
200	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 451-460.e2.	0.2	9
201	The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM). Blood Cancer Journal, 2021, 11, 158.	2.8	9
202	Autologous Stem Cell Transplantation In Immunoglobulin Light Chain Amyloidosis With Factor X Deficien. Blood, 2013, 122, 2151-2151.	0.6	9
203	Bendamustine rituximab (BR) versus ibrutinib (ibr) as primary therapy for WaldenstrÃ¶m macroglobulinemia (WM): An international collaborative study.. Journal of Clinical Oncology, 2022, 40, 7566-7566.	0.8	9
204	Another bidder (BDR) revisits. Blood, 2017, 129, 398-400.	0.6	8
205	Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma. Blood Cancer Journal, 2017, 7, e569-e569.	2.8	8
206	Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. Leukemia, 2018, 32, 1421-1426.	3.3	8
207	Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation. Bone Marrow Transplantation, 2018, 53, 155-161.	1.3	8
208	Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75. Biology of Blood and Marrow Transplantation, 2018, 24, 2157-2159.	2.0	8
209	Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 53-56.	0.2	8
210	Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. Bone Marrow Transplantation, 2020, 55, 2132-2137.	1.3	8
211	The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?. Blood Cancer Journal, 2020, 10, 52.	2.8	8
212	Partial response or better at sixÃ¶months is prognostic of superior progressionÃ¶free survival in WaldenstrÃ¶m macroglobulinaemia patients treated with ibrutinib. British Journal of Haematology, 2021, 192, 542-550.	1.2	8
213	Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. Leukemia, 2021, 35, 1428-1437.	3.3	8
214	Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design. Leukemia, 2021, 35, 3604-3607.	3.3	8
215	Comparison of the current renal staging, progression and response criteria to predict renal survival in <scp>AL</scp> amyloidosis using a <scp>Mayo</scp> cohort. American Journal of Hematology, 2021, 96, 446-454.	2.0	8
216	Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib. Blood, 2015, 126, 3050-3050.	0.6	8

#	ARTICLE	IF	CITATIONS
217	A Phase I/II Trial of Ixazomib (Ix), Pomalidomide (POM), and Dexamethasone (DEX), in Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients: Responses in Double/Triple Refractory Myeloma and Poor Risk Cytogenetics. <i>Blood</i> , 2016, 128, 3316-3316.	0.6	8
218	Rituximab-based maintenance therapy in Waldenström macroglobulinemia: A case control study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7559-7559.	0.8	8
219	Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. <i>Blood Cancer Journal</i> , 2021, 11, 186.	2.8	8
220	Waldenström Macroglobulinemia in the Very Elderly (≥75 years):Clinical Characteristics and Outcomes. <i>Blood</i> , 2020, 136, 44-45.	0.6	8
221	Current approach to Waldenström Macroglobulinemia. <i>Cancer Treatment and Research Communications</i> , 2022, 31, 100527.	0.7	8
222	Melflufen for multiple myeloma: a promise unfulfilled?. <i>Lancet Haematology</i> ,the, 2022, 9, e82-e84.	2.2	8
223	Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100. <i>Leukemia</i> , 2022, 36, 1429-1431.	3.3	8
224	Acalabrutinib in mantle cell lymphoma. <i>Lancet, The</i> , 2018, 391, 633-634.	6.3	7
225	Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response. <i>Bone Marrow Transplantation</i> , 2019, 54, 442-447.	1.3	7
226	Characteristics of long-term survivors with multiple myeloma: A National Cancer Data Base analysis. <i>Cancer</i> , 2019, 125, 3574-3581.	2.0	7
227	Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. <i>Leukemia</i> , 2019, 33, 1268-1272.	3.3	7
228	Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1077-1081.	1.3	7
229	The race to stymie BTK: zanu zings. <i>Blood</i> , 2020, 136, 1997-1999.	0.6	7
230	Continued Improvement in Survival in Multiple Myeloma and the Impact of Novel Agents. <i>Blood</i> , 2012, 120, 3972-3972.	0.6	7
231	Impact Of FISH Abnormalities On Response To Lenalidomide In Patients With Multiple Myeloma. <i>Blood</i> , 2013, 122, 3210-3210.	0.6	7
232	A phase I/II study of ixazomib (Ix) pomalidomide (POM) dexamethasone (DEX) in relapsed refractory (R/R) multiple myeloma: Initial results.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8008-8008.	0.8	7
233	Use of Artificial Intelligence Electrocardiography to Predict Atrial Fibrillation (AF) in Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2020, 136, 50-51.	0.6	7
234	Kidney Transplant Outcomes of Patients With Multiple Myeloma. <i>Kidney International Reports</i> , 2022, 7, 752-762.	0.4	7

#	ARTICLE	IF	CITATIONS
235	Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab. <i>Leukemia</i> , 2022, 36, 1426-1428.	3.3	7
236	Estimating the annual volume of hematologic cancer cases per hematologist oncologist in the United States: are we treating rare cancers too rarely?. <i>Leukemia and Lymphoma</i> , 2017, 58, 251-252.	0.6	6
237	Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. <i>Leukemia</i> , 0, , .	3.3	6
238	The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 770.e1-770.e7.	0.6	6
239	Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma. <i>Blood</i> , 2019, 134, 4106-4106.	0.6	6
240	In Patients with Light-Chain (AL) Amyloidosis Myocardial Contraction Fraction (MCF) Is a Simple, but Powerful Prognostic Measure That Can be Calculated from a Standard Echocardiogram (ECHO). <i>Blood</i> , 2015, 126, 1774-1774.	0.6	6
241	Prognostic significance of acquired 1q22 gain in multiple myeloma. <i>American Journal of Hematology</i> , 2021, , .	2.0	6
242	Impact of maintenance therapy post autologous stem cell transplantation for multiple myeloma in early and delayed transplant. <i>Bone Marrow Transplantation</i> , 2022, 57, 803-809.	1.3	6
243	Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS). <i>Blood Cancer Journal</i> , 2022, 12, 62.	2.8	6
244	Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1143-1156.	1.1	5
245	Outcome of very young (<40 years) patients with immunoglobulin light chain (AL) amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 50-51.	1.4	5
246	The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. <i>American Journal of Hematology</i> , 2017, 92, E507-E512.	2.0	5
247	Defining Lymphoplasmacytic Lymphoma. <i>American Journal of Clinical Pathology</i> , 2018, 150, 168-176.	0.4	5
248	Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2020, 55, 1297-1304.	1.3	5
249	Acute Acquired Fanconi Syndrome in Multiple Myeloma After Hematopoietic Stem Cell Transplantation. <i>Kidney International Reports</i> , 2021, 6, 857-864.	0.4	5
250	Efficacy of Daratumumab-Based Regimens for the Treatment of Plasma Cell Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 355-360.	0.2	5
251	Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic Experience. <i>Blood</i> , 2015, 126, 4197-4197.	0.6	5
252	Efficacy of Carfilzomib (K), Pomalidomide (P), and Dexamethasone (d) in Heavily Pretreated Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) in a Real World Setting. <i>Blood</i> , 2016, 128, 3337-3337.	0.6	5

#	ARTICLE	IF	CITATIONS
253	Phase 1/2 trial of ixazomib, cyclophosphamide, and dexamethasone for newly diagnosed multiple myeloma (NDMM).. Journal of Clinical Oncology, 2016, 34, 8002-8002.	0.8	5
254	Characteristics and risk factors for thrombosis in <scp>POEMS</scp> syndrome: A retrospective evaluation of 230 patients. American Journal of Hematology, 2022, 97, 209-215.	2.0	5
255	Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome. American Journal of Hematology, 2022, , .	2.0	5
256	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 40-41.	1.4	4
257	Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 183-188.	1.4	4
258	Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. Bone Marrow Transplantation, 2018, 53, 326-333.	1.3	4
259	Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma. Leukemia and Lymphoma, 2019, 60, 2960-2967.	0.6	4
260	Implications and outcomes of MRDâ€negative multiple myeloma patients with immunofixation positivity. American Journal of Hematology, 2020, 95, E60-E62.	2.0	4
261	Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1402-1405.	2.0	4
262	Characterization and prognostic implication of delayed complete response in AL amyloidosis. European Journal of Haematology, 2021, 106, 354-361.	1.1	4
263	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone for Treatment of Previously Untreated Light Chain Amyloidosis. Blood, 2020, 136, 52-53.	0.6	4
264	Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma. Blood, 2020, 136, 36-37.	0.6	4
265	Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM). Blood, 2020, 136, 30-31.	0.6	4
266	Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM). Blood, 2016, 128, 2968-2968.	0.6	4
267	Importance of pharmacovigilance in the era of small molecules: Role of pharmacist consultation with ixazomib (IXA) in multiple myeloma (MM).. Journal of Clinical Oncology, 2016, 34, 8058-8058.	0.8	4
268	Outcomes with rituximab plus bendamustine (R-Benda), dexamethasone, rituximab, cyclophosphamide (DRC), and bortezomib, dexamethasone, rituximab (BDR) as primary therapy in patients with Waldenstrom macroglobulinemia (WM).. Journal of Clinical Oncology, 2019, 37, 7509-7509.	0.8	4
269	Pilot Implementation of Remote Patient Monitoring Program for Outpatient Management of CAR-T Cell Therapy. Blood, 2021, 138, 568-568.	0.6	4
270	High frequency of central nervous system involvement in transformed WaldenstrÃ¶m macroglobulinemia. Blood Advances, 2022, 6, 3655-3658.	2.5	4

#	ARTICLE	IF	CITATIONS
271	Reply to Castillo et al.. American Journal of Hematology, 2018, 93, E71-E73.	2.0	3
272	Colon perforation in multiple myeloma patients â€“ A complication of highâ€“dose steroid treatment. Cancer Medicine, 2020, 9, 8895-8901.	1.3	3
273	Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma. Blood Cancer Journal, 2020, 10, 95.	2.8	3
274	Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide. European Journal of Haematology, 2021, 106, 433-436.	1.1	3
275	Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia. Leukemia and Lymphoma, 2021, 62, 308-315.	0.6	3
276	Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis. Transplantation and Cellular Therapy, 2021, 27, 589.e1-589.e6.	0.6	3
277	Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM). Blood, 2020, 136, 12-13.	0.6	3
278	Survival Outcomes Of Very Young (<40 years) Myeloma Patients. Blood, 2013, 122, 2136-2136.	0.6	3
279	Myelomatous Involvement Of The Central Nervous System: Mayo Clinic Experience. Blood, 2013, 122, 3119-3119.	0.6	3
280	Analysis of Serum Ferritin Levels As a Diagnostic Criteria for Hemophagocytic Lymphohistiocytosis (HLH) in Hospitalized Adult Patients. Blood, 2015, 126, 1014-1014.	0.6	3
281	Impact of Bone Marrow Plasmacytosis on Outcome in Patients with AL Amyloidosis Following Autologous Stem Cell Transplant. Blood, 2015, 126, 3177-3177.	0.6	3
282	Bortezomib Versus Non-Bortezomib Based Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis. Blood, 2016, 128, 3317-3317.	0.6	3
283	Evolving changes in M-protein (M), quantitative involved immunoglobulin (Ig), and hemoglobin (Hb) to identify patients (pts) with ultra high-risk smoldering multiple myeloma (UHR-SMM).. Journal of Clinical Oncology, 2016, 34, 8004-8004.	0.8	3
284	Trends in Multiple Myeloma Incidence in the United States (US): Demographic and Geographic Considerations and Focus on Young Adults. Blood, 2018, 132, 5575-5575.	0.6	3
285	Characteristics and outcome of patients with MYD88 wild-type WaldenstrÃ¶m Macroglobulinemia.. Journal of Clinical Oncology, 2020, 38, 8550-8550.	0.8	3
286	"Real-Life" Data of the Efficacy and Safety of Belantamab Mafodotin in Relapsed Multiple Myeloma- the Mayo Clinic Experience. Blood, 2021, 138, 1639-1639.	0.6	3
287	Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis. Leukemia, 2022, 36, 1058-1065.	3.3	3
288	Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation. Blood Cancer Journal, 2022, 12, 59.	2.8	3

#	ARTICLE	IF	CITATIONS
289	The <i>MYD88</i>^{L265P} conundrum in IgM monoclonal gammopathy of undetermined significance. <i>British Journal of Haematology</i> , 2019, 187, 413-415.	1.2	2
290	Predictors of short-term survival in Waldenström Macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 2975-2979.	0.6	2
291	Of lions, shar-pei, and doughnuts: a tale retold. <i>Blood</i> , 2020, 135, 1074-1076.	0.6	2
292	Outcomes of multiple myeloma patients with <scp>del 17p</scp> undergoing autologous stem cell transplantation. <i>American Journal of Hematology</i> , 2021, 96, E35-E38.	2.0	2
293	Retroperitoneal involvement with light chain amyloidosis- case series and literature review. <i>Leukemia and Lymphoma</i> , 2021, 62, 316-322.	0.6	2
294	Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis. <i>Leukemia and Lymphoma</i> , 2021, 62, 3011-3018.	0.6	2
295	Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States. <i>Blood</i> , 2019, 134, 72-72.	0.6	2
296	A Prospective Pilot Study of Ixazomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed or Relapsed/Refractory POEMS Syndrome. <i>Blood</i> , 2019, 134, 1846-1846.	0.6	2
297	Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma. <i>Blood</i> , 2019, 134, 4386-4386.	0.6	2
298	Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma. <i>Blood</i> , 2019, 134, 1905-1905.	0.6	2
299	MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients. <i>Blood</i> , 2020, 136, 48-49.	0.6	2
300	Therapy Related MDS/AML In Multiple Myeloma Patients In The Era Of Novel Agents. <i>Blood</i> , 2013, 122, 3117-3117.	0.6	2
301	Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenström Macroglobulinemia. <i>Blood</i> , 2016, 128, 2972-2972.	0.6	2
302	Bone and Joint Infections in Multiple Myeloma: A Retrospective Review of Patients at Mayo Clinic. <i>Blood</i> , 2016, 128, 5636-5636.	0.6	2
303	Daratumumab-based therapies in patients with AL amyloidosis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8053-8053.	0.8	2
304	Depth of Response in Waldenström Macroglobulinemia. <i>Blood</i> , 2018, 132, 4141-4141.	0.6	2
305	Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma. <i>Blood</i> , 2018, 132, 3160-3160.	0.6	2
306	Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma. <i>Blood</i> , 2021, 138, 1750-1750.	0.6	2

#	ARTICLE	IF	CITATIONS
307	Ocular Toxicity of Commercially Available Belantamab Mafodotin in Patients with Advanced Multiple Myeloma. <i>Blood</i> , 2021, 138, 2711-2711.	0.6	2
308	Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation. <i>American Journal of Hematology</i> , 2022, , .	2.0	2
309	Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2022, 63, 2422-2427.	0.6	2
310	Mantle cell lymphoma: a great masquerader. <i>International Journal of Hematology</i> , 2014, 100, 313-314.	0.7	1
311	Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 1663.	0.9	1
312	Bone and Joint Infections in Acute Myelogenous Leukemia: A Retrospective Review of Patients at Mayo Clinic. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	1
313	Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 44-45.	1.4	1
314	POEMS syndrome: An elusive diagnosis. <i>American Journal of Hematology</i> , 2017, 92, 1269-1270.	2.0	1
315	Fitting mSMART Into the Current Clinical Management of Waldenström Macroglobulinemia—Reply. <i>JAMA Oncology</i> , 2018, 4, 745.	3.4	1
316	Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 274-277.	1.3	1
317	Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 309.e1-309.e5.	0.6	1
318	Prognostic impact of depth of response in Waldenström macroglobulinemia patients treated with fixed duration chemoimmunotherapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8049-8049.	0.8	1
319	Chemotherapy-based stem cell mobilization in multiple myeloma patients treated with novel agents: The Mayo Clinic experience.. <i>Journal of Clinical Oncology</i> , 2021, 39, e20000-e20000.	0.8	1
320	IgM Associated Light Chain (AL) Amyloidosis: Delineating Disease Biology with Clinical, Genomic and Bone Marrow Morphological Features. <i>Blood</i> , 2018, 132, 4460-4460.	0.6	1
321	Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis. <i>Blood</i> , 2019, 134, 4334-4334.	0.6	1
322	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). <i>Blood</i> , 2020, 136, 7-8.	0.6	1
323	Presence of a Measurable M-Spike before Autologous Stem Cell Transplantation Is Associated with Shorter Survival in Patients with Light Chain Amyloidosis. <i>Blood</i> , 2020, 136, 22-23.	0.6	1
324	Survival After Second, Third, and Fourth Line Therapy Better Than Expected in Patients with Previously Treated AL Amyloidosis Who Were Not Transplant Candidates At Diagnosis.. <i>Blood</i> , 2012, 120, 946-946.	0.6	1

#	ARTICLE	IF	CITATIONS
325	Soluble ST2 (sST2) Is a Novel Valuable Prognostic Marker Among Patients With Immunoglobulin Light Chain (AL) Amyloidosis. <i>Blood</i> , 2013, 122, 3095-3095.	0.6	1
326	Necrobiotic Xanthogranuloma (NXG) Associated with Monoclonal Gammopathies (MG): Clinical Features and Treatment Outcomes. <i>Blood</i> , 2015, 126, 1830-1830.	0.6	1
327	Predictors of Early Relapse Following Initial Therapy for Systemic Immunoglobulin Light Chain Amyloidosis. <i>Blood</i> , 2016, 128, 2082-2082.	0.6	1
328	Clinical Presentation and Outcomes of Patients with Light Chain Amyloidosis Who Have Non-Evaluable Free Light Chains at Diagnosis. <i>Blood</i> , 2016, 128, 3272-3272.	0.6	1
329	Practice Patterns of Re-Initiation of Therapy at Time of Relapse or Progression Post- Autologous Stem Cell Transplant (ASCT) Among Patients with AL Amyloidosis. <i>Blood</i> , 2016, 128, 3444-3444.	0.6	1
330	Effect of Standard Dose Versus Risk Adapted Melphalan Conditioning on Outcomes in Systemic AL Amyloidosis Patients Undergoing Frontline Autologous Stem Cell Transplant Based on Revised Mayo Stage. <i>Blood</i> , 2016, 128, 4627-4627.	0.6	1
331	Quantification of circulating clonal plasma cells (cPCs) via multiparametric flow cytometry (MFC) to identify patients with smoldering multiple myeloma (SMM) at high risk of progression.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8015-8015.	0.8	1
332	Daratumumab-based combination therapies (DCT) in heavily-pretreated patients (pts) with relapsed and/or refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8038-8038.	0.8	1
333	Factors predicting organ response in light chain amyloidosis (AL).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8048-8048.	0.8	1
334	Dexamethasone, rituximab and cyclophosphamide (DRC) in relapsed/refractory (R/R) and treatment naïve (TN) Waldenström macroglobulinemia (WM).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7552-7552.	0.8	1
335	Sex-Based Disparities in Venous Thromboembolism Sociodemographics and Outcomes: A National Inpatient Sample (NIS)-Based Analysis. <i>Blood</i> , 2016, 128, 5918-5918.	0.6	1
336	Natural history of t(11;14) multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8014-8014.	0.8	1
337	Treatment Facility Volume and Outcomes in Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018, 132, 622-622.	0.6	1
338	Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting. <i>Blood</i> , 2018, 132, 1606-1606.	0.6	1
339	Development of Thrombocytopenia and Survival Outcomes in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018, 132, 1902-1902.	0.6	1
340	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018, 132, 2884-2884.	0.6	1
341	Prognosis of Patients with Waldenström Macroglobulinemia: A Simplified Model. <i>Blood</i> , 2018, 132, 4152-4152.	0.6	1
342	Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant. <i>Blood</i> , 2019, 134, 3171-3171.	0.6	1

#	ARTICLE	IF	CITATIONS
343	A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH. <i>Blood</i> , 2019, 134, 1800-1800.	0.6	1
344	Clinical Outcomes and Cytogenetic Features of Primary Plasma Cell Leukemia (pPCL) in the Era of Novel Agent Induction Therapy. <i>Blood</i> , 2019, 134, 5490-5490.	0.6	1
345	Second Line Treatment Strategies in Multiple Myeloma: A Referral-Center Experience. <i>Blood</i> , 2021, 138, 819-819.	0.6	1
346	High Frequency of CNS Involvement in Transformed Waldenström Macroglobulinemia. <i>Blood</i> , 2021, 138, 2526-2526.	0.6	1
347	Outcomes Following Biochemical or Clinical Progression in Patients with Multiple Myeloma. <i>Blood</i> , 2021, 138, 3760-3760.	0.6	1
348	Prognostic Impact of CD3 Count in Apheresis Collection in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant. <i>Blood</i> , 2021, 138, 3774-3774.	0.6	1
349	Single Cell Transcriptome Profile of Myeloma and Immune Cell Characteristics in Patients with Durable Response Post CART. <i>Blood</i> , 2021, 138, 3838-3838.	0.6	1
350	Unmet Needs in AL Amyloidosis: Outcomes in the Modern Era Among the Highest Risk, Newly Diagnosed AL Amyloidosis Patients. <i>Blood</i> , 2020, 136, 31-32.	0.6	1
351	Sarcopenia identified by computed tomography (CT) imaging using a machine learning-based convolutional neural network (CNN) algorithm impacts survival in patients with newly diagnosed multiple myeloma (NDMM).. <i>Journal of Clinical Oncology</i> , 2022, 40, 110-110.	0.8	1
352	Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8022-8022.	0.8	1
353	Phase II clinical trials for Waldenström's macroglobulinemia. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 537-547.	0.5	0
354	Bone and Joint Infections Among Hematopoietic Stem Cell Transplant (HSCT) Recipients. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
355	Impact of stratifying levels of serum lactate dehydrogenase (LDH) at diagnosis on the overall survival (OS) in newly diagnosed multiple myeloma (NDMM).. <i>Journal of Clinical Oncology</i> , 2021, 39, e20016-e20016.	0.8	0
356	Daratumumab for post-ASCT maintenance treatment of myeloma. <i>Lancet Oncology</i> , The, 2021, 22, 1345-1347.	5.1	0
357	Outcomes of Patients with POEMS Syndrome Treated Initially with Radiation. <i>Blood</i> , 2012, 120, 448-448.	0.6	0
358	Outcome of Adult Patients with Hemophagocytic Syndrome: A Tertiary Care Center Experience. <i>Blood</i> , 2012, 120, 1040-1040.	0.6	0
359	Importance of Achieving Sustained Stringent Complete Response (sCR) Following Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , 2012, 120, 1988-1988.	0.6	0
360	Effect Of Immediate Prior-Line Lenalidomide Or Thalidomide Therapy On Response To Pomalidomide In Multiple Myeloma. <i>Blood</i> , 2013, 122, 1979-1979.	0.6	0

#	ARTICLE	IF	CITATIONS
361	Long Term Response To Lenalidomide With and Without Continuous Therapy Among Patients With Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2013, 122, 3209-3209.	0.6	0
362	Prognostic Value Of Quantifying Circulating Plasma Cells By Multiparametric Flow Cytometry In Patients With Relapsed Multiple Myeloma. <i>Blood</i> , 2013, 122, 754-754.	0.6	0
363	Increased Circulating Plasma Cells On Multiparametric Flow Cytometry As An Independent Prognostic Biomarker In Newly Diagnosed Multiple Myeloma: Implications For Redefining High-Risk Myeloma. <i>Blood</i> , 2013, 122, 1842-1842.	0.6	0
364	Estimating the Annual Volume of Hematologic Cancer Cases per Hematologist-Oncologist in the United States: Are We Treating Rare Cancers Too Rarely?. <i>Blood</i> , 2015, 126, 3297-3297.	0.6	0
365	N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM). <i>Blood</i> , 2015, 126, 3292-3292.	0.6	0
366	AL Amyloidosis and Patient Reported Quality of Life. <i>Blood</i> , 2015, 126, 3317-3317.	0.6	0
367	Occurrence and Prognostic Significance of Cytogenetic Evolution in Patients with Multiple Myeloma. <i>Blood</i> , 2015, 126, 4176-4176.	0.6	0
368	Natural History of Amyloidosis Isolated to Fat and Bone Marrow Aspirate. <i>Blood</i> , 2015, 126, 5303-5303.	0.6	0
369	The Impact of Induction Regimen Choice on Transplant Outcome and Survival in Newly Diagnosed Multiple Myeloma in the Era of Novel Agents. <i>Blood</i> , 2015, 126, 3044-3044.	0.6	0
370	The impact of novel induction regimens on transplant outcome in newly diagnosed multiple myeloma after controlling for high-risk FISH cytogenetics.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8033-8033.	0.8	0
371	Prevalence and survival of smoldering multiple myeloma in the US: Analysis using a national dataset.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8035-8035.	0.8	0
372	Changes in serum alkaline phosphatase levels to predict response to ixazomib-based therapy in patients with newly diagnosed multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8053-8053.	0.8	0
373	Clinical utility of the revised international staging system (RISS) in newly diagnosed multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8017-8017.	0.8	0
374	Type 1 monoclonal cryoglobulinemia: Clinical presentation and outcomes.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8062-8062.	0.8	0
375	Immunoparesis in newly diagnosed AL amyloidosis as a marker for response and survival.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8016-8016.	0.8	0
376	Prognostic Implications of Multiple Cytogenetic High-Risk Abnormalities in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2016, 128, 5615-5615.	0.6	0
377	A Risk Stratification Model Using Quantification of Circulating Plasma Cells in Multiple Myeloma Prior to Autologous Stem Cell Transplantation in the Era of Novel Agents. <i>Blood</i> , 2016, 128, 996-996.	0.6	0
378	Thyroid Functional Abnormalities in Newly Diagnosed AL Amyloidosis: Frequency and Influence By Type of Organ Involvement and Disease Burden. <i>Blood</i> , 2016, 128, 3273-3273.	0.6	0

#	ARTICLE	IF	CITATIONS
379	Changes in Uninvolved Immunoglobulins during Multiple Myeloma Therapy. <i>Blood</i> , 2016, 128, 3251-3251.	0.6	0
380	Survival Trends in Young Patients with Waldenstrom Macroglobulinemia: Over 5 Decades of Experience. <i>Blood</i> , 2016, 128, 1810-1810.	0.6	0
381	Beta-Blockers Improved Survival Outcomes in Patients with Multiple Myeloma: A Retrospective Evaluation. <i>Blood</i> , 2016, 128, 3306-3306.	0.6	0
382	The Prognostic Significance of Polyclonal Bone Marrow Plasma Cells in Patients with Actively Relapsing Multiple Myeloma. <i>Blood</i> , 2016, 128, 1194-1194.	0.6	0
383	Fluorescence in-Situ Hybridization (FISH) Analysis in Untreated AL Amyloidosis Has an Independent Prognostic Impact By Abnormality Type and Treatment Category. <i>Blood</i> , 2016, 128, 3269-3269.	0.6	0
384	Treatment Patterns and Outcomes Following Initial Relapse in Patients with Relapsed Systemic Immunoglobulin Light Chain Amyloidosis. <i>Blood</i> , 2016, 128, 3338-3338.	0.6	0
385	Predicting Poor Overall Survival in Patients with Newly Diagnosed Multiple Myeloma and Standard-Risk Cytogenetics Treated with Novel Agents. <i>Blood</i> , 2016, 128, 3255-3255.	0.6	0
386	Outcome of Very Young (â‰¥ 40 years) Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Case Control Study. <i>Blood</i> , 2016, 128, 5576-5576.	0.6	0
387	Impact of Melphalan-Based Chemotherapy on Stem Cell Collection in Patients with Light Chain Amyloidosis. <i>Blood</i> , 2016, 128, 2187-2187.	0.6	0
388	Bortezomib, Melphalan and Low Dose TBI Conditioning for Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma. <i>Blood</i> , 2016, 128, 2267-2267.	0.6	0
389	The use of proteasome inhibitors among patients with POEMS syndrome.. <i>Journal of Clinical Oncology</i> , 2017, 35, e19530-e19530.	0.8	0
390	Outcomes according to involved free light chain (FLC) levels in patients with normal FLC ratio after initial therapy in light chain amyloidosis (AL).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8049-8049.	0.8	0
391	Risk stratification by detection of clonal circulating plasma cells (CPCs) by multi-parametric flow cytometry (MFC) in light chain amyloidosis (AL).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8047-8047.	0.8	0
392	Prognostic impact of kinetics of circulating plasma cells before and after induction therapy in newly diagnosed multiple myeloma patients undergoing early transplantation.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8020-8020.	0.8	0
393	Overuse of organ biopsies in immunoglobulin light chain (AL) amyloidosis: The consequence of failure of early recognition.. <i>Journal of Clinical Oncology</i> , 2017, 35, e19532-e19532.	0.8	0
394	Smoldering Waldenström's macroglobulinemia (SWM): Analysis from the National Cancer Database (NCDB).. <i>Journal of Clinical Oncology</i> , 2017, 35, 1573-1573.	0.8	0
395	The impact of body mass index on the risk of early progression of smoldering multiple myeloma to symptomatic myeloma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8032-8032.	0.8	0
396	Utility and prognostic value of 18F-FDG PET/CT scan in patients with newly diagnosed multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8023-8023.	0.8	0

#	ARTICLE	IF	CITATIONS
397	Natural history of del53 multiple myeloma.. Journal of Clinical Oncology, 2018, 36, e20017-e20017.	0.8	0
398	Predictors of disease progression in smoldering Waldenström macroglobulinemia.. Journal of Clinical Oncology, 2018, 36, 7571-7571.	0.8	0
399	Duration of complete response (DurCR) impacts overall survival (OS) in multiple myeloma (MM).. Journal of Clinical Oncology, 2018, 36, 8045-8045.	0.8	0
400	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy.. Journal of Clinical Oncology, 2018, 36, 8030-8030.	0.8	0
401	Long-Term Survivorship with Active Multiple Myeloma. Blood, 2018, 132, 1912-1912.	0.6	0
402	Comparative Analysis of Staging Systems in AL Amyloidosis. Blood, 2018, 132, 3228-3228.	0.6	0
403	Early Prediction of Treatment Response in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 3159-3159.	0.6	0
404	Prognostic Significance of Early Immune Reconstitution in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 3158-3158.	0.6	0
405	Impact of Acquired Del(17p) in Patients with Multiple Myeloma. Blood, 2018, 132, 4449-4449.	0.6	0
406	Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience. Blood, 2018, 132, 2147-2147.	0.6	0
407	Long-Term AL Amyloidosis Survivors Among Non-Selected Referral Population. Blood, 2018, 132, 3226-3226.	0.6	0
408	Salvage Autologous Stem Cell Transplantation in Multiple Myeloma: Investigating the Impact of Pre-Transplant Therapy. Blood, 2018, 132, 4613-4613.	0.6	0
409	Expected Survival in Patients with Smoldering Multiple Myeloma and Multiple Myeloma. Blood, 2018, 132, 4497-4497.	0.6	0
410	Mass Spectrometry to Measure Response in Immunoglobulin Light Chain Amyloidosis (AL). Blood, 2018, 132, 4502-4502.	0.6	0
411	Prognostic Restaging at the Time of 2nd-Line Therapy in Patients with AL Amyloidosis. Blood, 2018, 132, 5594-5594.	0.6	0
412	Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy. Blood, 2018, 132, 3227-3227.	0.6	0
413	Plasma Cell Disorders in Patients with Age-Related Transthyretin (ATTRwt) Amyloidosis. Blood, 2018, 132, 5610-5610.	0.6	0
414	Immune System Profiling of Waldenstrom Macroglobulinemia (WM) and Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) Using Mass Cytometry (CyTOF). Blood, 2018, 132, 4138-4138.	0.6	0

#	ARTICLE	IF	CITATIONS
415	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). <i>Blood</i> , 2018, 132, 3268-3268.	0.6	0
416	Three Decades of Autologous Stem Cell Transplantation for Myeloma; Trends in Early Mortality and Survival. <i>Blood</i> , 2018, 132, 3436-3436.	0.6	0
417	Characterization of Exceptional Responders to Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , 2018, 132, 4615-4615.	0.6	0
418	Current Therapeutic Options in Waldenström Macroglobulinemia. <i>Oncology & Hematology Review</i> , 2019, 15, 39.	0.2	0
419	Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma. <i>Blood</i> , 2019, 134, 4505-4505.	0.6	0
420	Hypovitaminosis D Is Prevalent in Patients with Renal AL Amyloidosis and Associated with Non-t(11;14). <i>Blood</i> , 2019, 134, 5523-5523.	0.6	0
421	Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. <i>Blood</i> , 2019, 134, 1532-1532.	0.6	0
422	Metaphase Cytogenetics for Risk Stratification in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019, 134, 4396-4396.	0.6	0
423	Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition. <i>Blood</i> , 2019, 134, 3080-3080.	0.6	0
424	Long Non-Coding RNA Expression in Waldenstrom Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance. <i>Blood</i> , 2019, 134, 2774-2774.	0.6	0
425	Determinants of Clinical Trial Participation and Impact on Survival Outcomes Among Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019, 134, 5833-5833.	0.6	0
426	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma. <i>Blood</i> , 2019, 134, 1904-1904.	0.6	0
427	Increased Mean Corpuscular Volume Is an Independent Predictor for Worse Overall Survival in Patients with Newly Diagnosed Light Chain Amyloidosis. <i>Blood</i> , 2019, 134, 5532-5532.	0.6	0
428	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019, 134, 2197-2197.	0.6	0
429	Use of Maintenance Therapy Post Autologous Stem Cell Transplantation Outside of Clinical Trial Setting for Multiple Myeloma: Single Institution Experience. <i>Blood</i> , 2019, 134, 2013-2013.	0.6	0
430	Tracking Daratumumab Clearance Using Mass Spectrometric Approaches: Implications on M Protein Monitoring and Reusing Daratumumab. <i>Blood</i> , 2021, 138, 2707-2707.	0.6	0
431	An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 (VSV-IFN β -NIS). <i>Blood</i> , 2021, 138, 1333-1333.	0.6	0
432	Prognostic Role of IL-6 in POEMS Syndrome. <i>Blood</i> , 2021, 138, 2700-2700.	0.6	0

#	ARTICLE	IF	CITATIONS
433	Monoclonal Proteinuria Predicts Progression Risk in Asymptomatic Multiple Myeloma with a Free Light Chain Ratio ≥ 100 . Blood, 2021, 138, 1617-1617.	0.6	0
434	Amyloidosis Composite Response Score Incorporating the Depth of Organ Response. Blood, 2021, 138, 3805-3805.	0.6	0
435	Impact of Achieving an Early Complete Response in Multiple Myeloma and Predictors of Subsequent Outcome. Blood, 2021, 138, 3773-3773.	0.6	0
436	Prognostic Factors for Early (≤ 2 years) and Late (> 5 years) Relapse in Multiple Myeloma- Pivotal Role of Cytogenetic Changes. Blood, 2021, 138, 3761-3761.	0.6	0
437	Outcomes of Triple Class (Proteasome Inhibitor, IMiDs and Monoclonal Antibody) Refractory Patients with Multiple Myeloma. Blood, 2021, 138, 1632-1632.	0.6	0
438	The Prognostic Utility of Serial MASS-FIX in Multiple Myeloma. Blood, 2021, 138, 1619-1619.	0.6	0
439	Assessing the Prognostic Utility of the Mayo 2018 and IMWG 2020 Smoldering Multiple Myeloma Risk Stratification Scores When Applied Post Diagnosis. Blood, 2021, 138, 543-543.	0.6	0
440	Factors Associated with Renal Impairment at Diagnosis in Multiple Myeloma with Survival Trends over Last Two Decades. Blood, 2021, 138, 1630-1630.	0.6	0
441	Mortality Trends in Multiple Myeloma after the Introduction of Novel Therapies in the United States. Blood, 2021, 138, 119-119.	0.6	0
442	The Impact of the Central Carbon Energy Metabolism Transcriptome in the Pathogenesis and Outcomes of Multiple Myeloma. Blood, 2021, 138, 2650-2650.	0.6	0
443	Comparison of Conventional Xrays with CT Based Approaches for Detection of Lytic Lesions in Multiple Myeloma. Blood, 2020, 136, 27-28.	0.6	0
444	A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders. Blood, 2020, 136, 44-45.	0.6	0
445	Prognostic Impact of PET Findings Post-Transplant in Multiple Myeloma. Blood, 2020, 136, 15-16.	0.6	0
446	Treatments and Outcomes of Newly Diagnosed Multiple Myeloma Patients > 75 Years Old: A Retrospective Analysis. Blood, 2020, 136, 14-15.	0.6	0
447	Prognostic Restaging after Treatment Initiation in Patients with AL Amyloidosis. Blood, 2020, 136, 6-7.	0.6	0
448	Outcomes of Multiple Myeloma Patients with Del 17p Undergoing Autologous Stem Cell Transplantation. Blood, 2020, 136, 21-22.	0.6	0
449	A 3-Question Symptom Assessment Score Can Predict Outcomes in Newly Diagnosed Multiple Myeloma (MM). Blood, 2020, 136, 21-22.	0.6	0
450	Autologous Stem Cell Transplantation for Multiple Myeloma Patients Aged ≥ 75 Treated with Novel Agents. Blood, 2020, 136, 12-13.	0.6	0

#	ARTICLE	IF	CITATIONS
451	Retroperitoneal Involvement of Light Chain Amyloidosis-Case Series and Literature Review. Blood, 2020, 136, 37-38.	0.6	0
452	Prevalence of Familial Plasma Cell Disorders in Patients with Multiple Myeloma. Blood, 2020, 136, 1-2.	0.6	0
453	Decreased Cardiac Ejection Fraction Is Associated with Worse Survival in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. Blood, 2020, 136, 41-42.	0.6	0
454	Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis. Bone Marrow Transplantation, 2022, , .	1.3	0
455	Impact of high-dose melphalan followed by autologous stem cell transplant in producing MRD negative complete response in newly diagnosed multiple myeloma.. Journal of Clinical Oncology, 2022, 40, e20001-e20001.	0.8	0
456	Insurance-based disparities in Waldenstrom Macroglobulinemia: An NCDB analysis.. Journal of Clinical Oncology, 2022, 40, e19562-e19562.	0.8	0